Harrow to Acquire Global Rights to TYRVAYA from Viatris for up to $100M

Harrow, Inc. has entered into a definitive agreement with Viatris Inc. to acquire the global rights to TYRVAYA®, a nasal spray for the treatment of dry eye disease, for a total potential consideration of up to $100 million. The acquisition is intended to expand Harrow's dry eye product portfolio, complementing its existing VEVYE® franchise.

Key Details

• Financial Terms: The deal includes a $30 million upfront cash payment at closing and up to $70 million in contingent milestone payments based on future net sales.
• Acquired Asset: Harrow will acquire the assets related to TYRVAYA®, including regulatory approvals, intellectual property, and inventory.
• Timeline: The agreement was signed on August 3, 2026, and the acquisition is expected to close in the second half of 2026.